The global ATTR drugs market size stood at USD 585 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
ATTR amyloidosis is a rare disease, caused by the build-up of abnormal protein deposits in various tissues of the body. Amyloid deposits cause disorder by damaging the structure and the function of the organs where they are found, and they can affect almost any part of the body. The global ATTR is expected to experience robust growth post the launch of ATTR therapeutic drugs, primarily due to increasing African American population, increasing health care expenditure, and accelerating economic growth. However, the growth of this budding market is hindered by the stringent regulations, high cost of ATTR drugs, misdiagnosis of ATTR disorder and limitation of clinical trials
The global transthyretin amyloidosis treatment market is likely to be driven by an increase in the prevalence of disease, rise in the population with African origin, increase in awareness, improvement in diagnostic procedures, improving health care services, rapid economic growth in developing countries, and rise in research and development activity. The main driver of the ATTR market expansion will be the approval and launch of the RNA interference therapeutics both ATTR polyneuropathy and ATTR cardiomyopathy. The approval of other pipeline agents of varying mechanism will also drive growth due to the current scarcity of the ATTR market. Another prominent contributor to sales growth the increase in diagnosed prevalence across the 7MM. This increase will be caused by improved understanding and awareness of the disease alongside campaigns by drug developers to increase genetic testing. The key market opportunities lie in addressing unmet needs through the development of efficacious therapies for clearing already deposited amyloid and increasing the number of therapies approved for ATTR cardiomyopathy